Cardiogenic shock (CS) is a highly complex state of multiorgan hypoperfusion. With multiple etiologies and varying pathologies leading to different severity of shock, mortality remains high (33–46 %) . Acute mechanical mitral pathology leading to cardiogenic shock complicates the matter further, exacerbating mortality with or without valve surgery . In the current era of mechanical circulatory support (MCS), several devices including intra-aortic balloon pump (IABP), percutaneous left ventricular assist devices such as Impella, extracorporeal membrane oxygenation (ECMO), and others alone or in combination have been shown to slow down the clinical deterioration of patients. However, even MCS in the absence of managing the patients' acute mitral pathology is associated with high mortality. Transcatheter edge-to-edge repair (TEER) has been identified as an alternative mitral intervention in patients who are high and prohibitive risk for surgery. Yet patients with cardiogenic shock were excluded from all TEER studies.